From Boeing To Nike, Jim Cramer Spotlights Dow's Biggest Q1 Flops: 'Nothing Pristine About This List'
Portfolio Pulse from Benzinga Neuro
Jim Cramer reviewed the Dow Jones Industrial Average's five worst-performing stocks in Q1 2024 on CNBC's 'Mad Money'. The stocks include Boeing, Nike, Intel, Apple, and UnitedHealth Group. Despite their poor performance, Cramer believes these companies could be at a turning point. He highlighted Boeing's plane malfunctions, Nike's competition challenges, Intel's potential rally, Apple's long-term value despite short-term challenges, and UnitedHealth's strong management despite facing higher medical costs.
April 02, 2024 | 4:13 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Boeing's ongoing plane malfunctions could keep it on the poorly performing list, according to Jim Cramer.
Boeing's highlighted malfunctions could deter investor confidence, potentially impacting its stock negatively in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Nike faces fierce competition and consumer shift towards cheaper alternatives, raising concerns about its performance.
The competition and consumer behavior changes mentioned by Cramer could lead to negative short-term impacts on Nike's stock.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Despite short-term challenges, Jim Cramer believes in Apple's long-term value, highlighting potential collaborations with Nvidia.
Apple's long-term investment appeal and potential collaborations, despite short-term challenges, suggest a positive short-term outlook.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
Intel could see a rally due to favorable year-over-year comparisons and a recent price target increase by UBS.
The positive outlook from UBS and favorable comparisons could lead to a short-term positive impact on Intel's stock.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
UnitedHealth faces higher medical costs but its strong management could lead to a rebound, making it the most likely to recover among the five.
UnitedHealth's strong management and potential for rebound, despite higher medical costs, indicate a positive short-term stock impact.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90